Hostname: page-component-6766d58669-7cz98 Total loading time: 0 Render date: 2026-05-19T07:22:59.376Z Has data issue: false hasContentIssue false

Confirmation and Characterization of Non–target site Resistance to Fomesafen in Palmer amaranth (Amaranthus palmeri)

Published online by Cambridge University Press:  21 September 2018

Vijay K. Varanasi*
Affiliation:
Postdoctoral Research Associate, Department of Crop, Soil, and Environmental Sciences, University of Arkansas, Fayetteville, AR, USA
Chad Brabham
Affiliation:
Postdoctoral Research Associate, Department of Crop, Soil, and Environmental Sciences, University of Arkansas, Fayetteville, AR, USA
Jason K. Norsworthy
Affiliation:
Professor and Elms Farming Chair of Weed Science, Department of Crop, Soil, and Environmental Sciences, University of Arkansas, Fayetteville, AR, USA
*
Author for correspondence: Vijay K. Varanasi, Altheimer Laboratory, 1366 West Altheimer Drive, Fayetteville, AR 72704. (Email: varanasi@uark.edu)
Rights & Permissions [Opens in a new window]

Abstract

Palmer amaranth (Amaranthus palmeri S. Watson), a dioecious summer annual species, is one of the most troublesome weeds in U.S. cropping systems. The evolution of resistance to protoporphyrinogen oxidase inhibitors in A. palmeri biotypes is a major cause of concern to soybean [Glycine max (L.) Merr.] and cotton (Gossypium hirsutum L.) growers in the midsouthern United States. The objective of this study was to confirm and characterize the non–target site mechanism in a fomesafen-resistant accession from Randolph County, AR (RCA). A dose–response assay was conducted to assess the level of fomesafen resistance, and based on the GR50 values, the RCA accession was 18-fold more resistant to fomesafen than a susceptible (S) biotype. A TaqMan allelic discrimination assay and sequencing of the target-site genes PPX2 and PPX1 revealed no known or novel target-site mutations. An SYBR Green assay indicated no difference in PPX2 gene expression between the RCA and S biotypes. To test whether fomesafen resistance is metabolic in nature, the RCA and the S biotypes were treated with different cytochrome P450 (amitrole, piperonyl butoxide [PBO], malathion) and glutathione S-transferase (GST) (4-chloro-7-nitrobenzofurazan [NBD-Cl]) inhibitors, either alone or in combination with fomesafen. Malathion followed by (fb) fomesafen in RCA showed the greatest reduction in survival (67%) and biomass (86%) compared with fomesafen alone (45% and 66%, respectively) at 2 wk after treatment. Interestingly, NBD-Cl fb fomesafen also resulted in low survival (35%) compared with the fomesafen-only treatment (55%). Applications of malathion or NBD-Cl preceding fomesafen treatment resulted in reversal of fomesafen resistance, indicating the existence of cytochrome P450– and GST-based non–target site mechanisms in the RCA accession. This study confirms the first case of non–target site resistance to fomesafen in A. palmeri.

Information

Type
Research Article
Copyright
© Weed Science Society of America, 2018 
Figure 0

Table 1 Primers used for amplifying and sequencing the two isoforms of the protoporphyrinogen oxidase–coding gene PPX in Amaranthus palmeri, with the quantitative PCR primers used for measuring PPX2 gene expression in fomesafen-resistant (from Randolph County, AR) and susceptible biotypes also shown.

Figure 1

Table 2 Effects of cytochrome P450 (malathion, PBO, amitrole) and glutathione S-transferase (NBD-Cl) inhibitors on the percent survival and biomass reduction of the RCA (fomesafen-resistant from Randolph County, AR) and susceptible (S) Amaranthus palmeri.ab

Figure 2

Figure 1 Dose–response assay using four-parameter log-logistic model for the Amaranthus palmeri RCA (fomesafen-resistant from Randolph County, AR) and susceptible accessions.

Figure 3

Figure 2 TaqMan quantitative PCR assay for detection of ΔG210 and R128G/M mutations in the PPX2 gene of the Amaranthus palmeri RCA (fomesafen-resistant from Randolph County, AR) biotype. Each of the gray dots at the top left corner of the scatter plot represents an individual plant that survived the field rate of fomesafen (Flexstar® at 395 g ha−1). Note the absence of any resistant alleles for ΔG210 and R128G/M mutations. The strength of the amplification signal is measured in terms of relative fluorescence units (RFU). Blue dots at the bottom left indicate no signal from the genomic DNA.

Figure 4

Figure 3 Sequencing of the PPX2 gene from five fomesafen-resistant (numbered 1, 2, 5, 10, and 11) Amaranthus palmeri individuals from the RCA (from Randolph County, AR) accession. Note the absence of ΔG210 (no glycine deletion) and R128G/M (no arginine substitutions) in the PPX2 gene sequence. cDNA sequences from the resistant plants were compared with a known susceptible (SUS).

Figure 5

Figure 4 PPX2 gene expression levels in the RCA (fomesafen-resistant from Randolph County, AR) and susceptible (S) biotypes of Amaranthus palmeri. Gene expression was measured relative to the reference gene (β-tubulin). Data represent means of three biological samples, and errors bars represent SE.

Figure 6

Figure 5 RCA (fomesafen-resistant Amaranthus palmeri biotype from Randolph County, AR) plants treated with P450 (amitrole, PBO, malathion) and glutathione S-transferase (NBD-Cl) inhibitors. The treatments included fomesafen (Flexstar® at 263 g ai ha−1) alone, amitrole (13.1 g ha−1) followed by (fb) fomesafen, PBO (1,500 g ai ha−1) fb fomesafen, malathion (1,500 g ha−1) fb fomesafen, and NBD-Cl (270 g ai ha−1) fb fomesafen. Amitrole, 3-amino-1,2,4-triazole; NBD-Cl, 4-chloro-7-nitrobenzofurazan; PBO, piperonyl butoxide.

Figure 7

Figure 6 RCA (fomesafen-resistant Amaranthus palmeri biotype from Randolph County, AR) plants treated with the P450 inhibitor malathion (1,500 g ha−1), fomesafen (Flexstar® at 263 g ha−1), or malathion followed by fomesafen. Picture taken at 2 wk after treatment.

Figure 8

Figure 7 RCA (fomesafen-resistant Amaranthus palmeri biotype from Randolph County, AR) plants treated with the glutathione S-transferase inhibitor 4-chloro-7-nitrobenzofurazan (NBD-Cl; 270 g ha−1), fomesafen (Flexstar® at 263 g ha−1), or NBD-Cl followed by fomesafen. Picture taken at 2 wk after treatment.